Individualizing Treatment Approaches in MPN
EP. 1: An Overview of Myeloproliferative Neoplasms
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Srdan Verstovsek, MD, PhD, provides an overview of the similarities and differences between myeloproliferative neoplasms, including polycythemia vera, myelofibrosis, and essential thrombocythemia.
EP. 2: Diagnosis and Evaluation in Polycythemia Vera
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.
EP. 3: Therapeutic Considerations in Polycythemia Vera
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.
EP. 4: PV Progression and Guideline-Directed Management
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.
EP. 5: Polycythemia Vera: An Update on Clinical Trials
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.
EP. 6: Real-World Use of Ruxolitinib in Polycythemia Vera
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Experts give real-world insight in using ruxolitinib in patients with polycythemia vera.
EP. 7: Emerging Therapeutic Options in Polycythemia Vera
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center What to look forward to in the polycythemia vera space, including new clinical trials.
EP. 8: Goals in Treating Low-Risk Primary Myelofibrosis
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic.
EP. 9: Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.
EP. 10: A Look at Fedratinib and the JAKARTA Trials
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice.
EP. 11: COMFORT Data and Ruxolitinib in Myelofibrosis
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.
EP. 12: The Role of Transplant in Myelofibrosis
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Experts discuss the role of transplant and evaluating options in patients with myelofibrosis.
EP. 13: A Review of Pacritinib and PACIFICA Data
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.
EP. 14: Ongoing Unmet Needs and New Approaches in Myelofibrosis
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.
EP. 15: Essential Thrombocythemia: An Overview
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Expert discusses risk-stratification models, prognosis, and the management of complications in essential thrombocythemia.
EP. 16: The Treatment Spectrum in Essential Thrombocythemia
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea.
EP. 17: Unmet Needs and Looking Ahead in Essential Thrombocythemia
BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center Unmet needs and current areas that are being studied in in essential thrombocythemia.
